Polio 01 Brooks 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

2

Download PDF ↗ Live URL (may be dead)

Document text

Centers for Disease Control and Prevention
National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention
National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention 
National Center for Immunization and Respiratory Diseases 
ACIP Polio Vaccination Work Group 
Oliver Brooks, MD, FAAP 
ACIP Meeting February 23, 2023 
Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. 

           
          
         
      
            
         
             
               
   Polio Vaccination Work Group Terms of Reference 
Policy topics under consideration: 
1) Whether more specific guidance on adult vaccination , including use of adult 
booster doses, can be provided in the context of circulating poliovirus. 
2) Whether adults who are immunocompromised should be recommended an 
additional adult booster of a polio-containing vaccine. 
3) Whether fractional doses of IPV (fIPV), as prequalified by WHO, should m eet polio 
vaccination requirements, including for people immigrating to the United States. 
4) Consider criteria under which novel Oral Polio Vaccine type 2 (nOPV2) might be 
used in areas with outbreaks or persistent circulation of poliovirus.